心脏交感活动和高血压左心室高血压之间的关系
Markus P Schlaich1, David M Kaye, Elisabeth Lambert
1Human Neurotransmitter Laboratory, Baker Heart Research Institute and Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria 8008, Australia. markus.schlaich@baker.edu.au
Circulation
|July 9, 2003
概括
高血压诱导的左心室缩与心脏交感活动的增加有关. 这表明,心脏中上腺素释放量的增加有助于左心室缩的发展.
科学领域:
- 心脏病学 心脏病学
- 高血压研究 高血压研究
- 自主神经系统研究 自主神经系统研究
背景情况:
- 左心室 (LV) 缩是高血压患者心血管事件的重要危险因素.
- 同情激活在人体LV缩的发展中的作用需要进一步验证.
研究的目的:
- 为了研究和比较高血压患者的系统和区域交感活动,有和没有左心室缩.
- 为了确定同情活动与高血压中左心室质量之间的关系.
主要方法:
- 采用放射性追踪剂稀释方法和微神经图来评估同情活动.
- 与三个组进行了比较:高血压与LV缩 (EH+),高血压没有LV缩 (EH-),和正常血压对照 (NT).
- 测量了LV质量指数,全身和脏的上腺素溢出,肌肉交感神经活动和心脏的上腺素溢出.
主要成果:
- 肌肉交感神经活动和心脏上腺素溢出仅在高血压组与LV缩 (EH+) 中显著增加.
- 在所有受试者中,心脏北上腺素溢出与LV质量指数呈正相关性.
- 虽然在两组高血压患者中,全身和上上的溢出量都较高,但在EH+患者中,心脏特异性活性显著增加.
结论:
- 高血压左心室缩与主要局限于心脏的同情活动有关.
- 心脏释放的北上腺素增加似乎是高血压患者左心室缩发展的关键因素.
相关概念视频
Sympathetic Activation
The sympathetic division can influence tissues and organs by releasing norepinephrine at peripheral synapses and distributing epinephrine and norepinephrine through the bloodstream. In times of crisis or stress, sympathetic activation occurs, which is regulated by sympathetic centers in the hypothalamus. As a result, sympathetic activation prepares the body for physical exertion, rapid ATP production, and heightened alertness, allowing individuals to respond effectively to challenging or...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...


